Mereo BioPharma gets Nasdaq extension to regain $1 minimum bid compliance - MREO News | RalliesMereo BioPharma gets Nasdaq extension to regain $1 minimum bid compliance
M
MREO• Nasdaq gives Mereo BioPharma more time on minimum bid price
- Mereo BioPharma received a Nasdaq notice extending its deadline to regain the $1 minimum bid-price requirement to Feb. 16, 2027.
- Compliance requires the ADS closing bid price to hold at $1 or more for at least 10 consecutive business days.
- Failure to regain compliance by the deadline triggers a Nasdaq delisting notice, with an option to appeal to a hearings panel.
- The notices do not immediately affect the ADS listing on the Nasdaq Capital Market.
•
